Vorapaxar: first global approval.
Poole RM, Elkinson S.
Drugs · review; journal article · DOI 10.1007/s40265-014-0252-2 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för vorapaxar sulfate. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
8 träffarNew antithrombotics for secondary prevention of acute coronary syndrome.
Goto S, Tomita A.
Clin Cardiol · research support, non-u.s. gov't; review-article; review; journal article · DOI 10.1002/clc.22233Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome).
Whellan DJ, Tricoci P, Chen E, Huang Z, Leibowitz D, Vranckx P, Marhefka GD, Held C, Nicolau JC, Storey RF, Ruzyllo W, Huber K, Sinnaeve P, Weiss AT, Dery JP, Moliterno DJ, Van de Werf F, Aylward PE, White HD, Armstrong PW, Wallentin L, Strony J, Harrington RA, Mahaffey KW.
J Am Coll Cardiol · comparative study; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1016/j.jacc.2013.10.048PAR-1 antagonists: current state of evidence.
Chatterjee S, Sharma A, Mukherjee D.
J Thromb Thrombolysis · review; journal article · DOI 10.1007/s11239-012-0752-4Protease-activated receptor-1 antagonists: focus on SCH 530348.
Sugunaraj JP, Mehta V, Kalra A, Sukhija R, Palaniswamy C.
Am J Ther · review; journal article · DOI 10.1097/mjt.0b013e3181ff7c16Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects.
Kosoglou T, Reyderman L, Tiessen RG, van Vliet AA, Fales RR, Keller R, Yang B, Cutler DL.
Eur J Clin Pharmacol · research support, non-u.s. gov't; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1007/s00228-011-1120-6Identification of human liver cytochrome P450 enzymes involved in the metabolism of SCH 530348 (Vorapaxar), a potent oral thrombin protease-activated receptor 1 antagonist.
Ghosal A, Lu X, Penner N, Gao L, Ramanathan R, Chowdhury SK, Kishnani NS, Alton KB.
Drug Metab Dispos · journal article · DOI 10.1124/dmd.110.035493Thrombin receptor antagonism -the potential of antiplatelet medication SCH 530348.
Macaulay TE, Allen C, Ziada KM.
Expert Opin Pharmacother · review; journal article · DOI 10.1517/14656561003720471